These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37566741)

  • 21. Successful treatment of Bowen disease with 1% tirbanibulin ointment.
    Blaya Imbernón D; Finello M; Labrandero Hoyos C; Lorca Spröhnle J; Casanova Esquembre A; Peñuelas Leal R; Grau Echevarría A; Hernández Bel P
    Clin Exp Dermatol; 2023 Sep; 48(10):1184-1186. PubMed ID: 37427812
    [No Abstract]   [Full Text] [Related]  

  • 22. [Topical cytostatic treatment of epitheliomas with a 5 per cent 5-fluorouracil ointment].
    Ebner H
    Z Haut Geschlechtskr; 1968 Sep; 43(18):757-62. PubMed ID: 5715906
    [No Abstract]   [Full Text] [Related]  

  • 23. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.
    Dao DD; Sahni VN; Sahni DR; Balogh EA; Grada A; Feldman SR
    Ann Pharmacother; 2022 Apr; 56(4):494-500. PubMed ID: 34301153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-fluorouracil ointment in tumors of the skin.
    De Moragas JM; Gimenez-Camarasa JM
    Dermatologica; 1970; 140():Suppl 1:65-74. PubMed ID: 5471365
    [No Abstract]   [Full Text] [Related]  

  • 25. [Topical therapy of precancerous lesions and skin carcinomas using a 5-fluorouracil ointment].
    Uthida-Tanaka AM; Nakamura S; de Britto-Costa R; de Tavares Mello E
    Hospital (Rio J); 1969 Dec; 76(6):2207-20. PubMed ID: 5309543
    [No Abstract]   [Full Text] [Related]  

  • 26. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
    Kempers S; DuBois J; Forman S; Poon A; Cutler E; Wang H; Cutler D; Fang J; Kwan R
    J Drugs Dermatol; 2020 Nov; 19(11):1093-1100. PubMed ID: 33196758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of basal cell carcinoma with 5-fluorouracil (5-FU) ointment.
    Reymann F
    Dermatologica; 1970; 140():Suppl 1:34-41. PubMed ID: 4919323
    [No Abstract]   [Full Text] [Related]  

  • 28. A follow-up study of treatment of basal cell carcinoma with 5-fluorouracil ointment.
    Reymann F
    Dermatologica; 1972; 144(4):205-8. PubMed ID: 5076720
    [No Abstract]   [Full Text] [Related]  

  • 29. [Value of the use of a 5-fluorouracil ointment in the treatment of basal cell epitheliomas in the aged].
    Gueguen MH
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(6):614-5. PubMed ID: 5161912
    [No Abstract]   [Full Text] [Related]  

  • 30. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction.
    Gross K; Kircik L; Kricorian G
    Dermatol Surg; 2007 Apr; 33(4):433-9; discussion 440. PubMed ID: 17430377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis.
    Yavel R; Overcash JS; Cutler D; Fang J; Zhi J
    Clin Pharmacol Drug Dev; 2022 Mar; 11(3):397-405. PubMed ID: 34783452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [5-fluorouracil ointment in the treatment of basal cell epithelioma].
    Chodynicka B; Szarmach H
    Przegl Dermatol; 1976; 63(5):691-7. PubMed ID: 1005763
    [No Abstract]   [Full Text] [Related]  

  • 33. Nodular superficial pigmented basal cell epitheliomas.
    Shelley WB; Wood MG
    Arch Dermatol; 1982 Nov; 118(11):928-30. PubMed ID: 7138053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorouracil paste treatment of thin basal cell carcinomas.
    Epstein E
    Arch Dermatol; 1985 Feb; 121(2):207-13. PubMed ID: 3977335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma.
    Mohs FE; Jones DL; Bloom RF
    Arch Dermatol; 1978 Jul; 114(7):1021-2. PubMed ID: 686718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis.
    Neale H; Michelon M; Jacob S; Pinkston M; Ukaegbu R; Zamor W; Morrison E; Deng A; Levin NA
    J Am Acad Dermatol; 2022 Aug; 87(2):423-425. PubMed ID: 34478783
    [No Abstract]   [Full Text] [Related]  

  • 38. Topical chemotherapy of basal and squamous skin cancers with 5-fluorouracil cream.
    Litwin MS; Krementz ET
    Panminerva Med; 1974 Mar; 16(3):84-5. PubMed ID: 4449647
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
    Kagy MK; Amonette R
    Dermatol Surg; 2000 Jun; 26(6):577-8; discussion 578-9. PubMed ID: 10848940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.